The purpose of this study is to determine the best combination of antiretroviral therapy for transgender women (TW) living with HIV who take feminization hormonal therapy (FHT). All participants will receive FHT. The study will determine if TW remain undetectable while receiving FHT for 48 weeks. Additionally, it will assess if hormone levels change based on the type of HIV medication taken.
Transgender women (TW) are the fastest-growing group of people with HIV (PWH). Historically, TW have had few opportunities to participate in research, and often experience barriers to engaging in care. More research is needed to help providers when it comes to choosing HIV medication in TW on Feminizing Hormone Therapy (FHT).
• 18 years or older • A person living with HIV taking certain ART medications with a viral load of less than 400 copies. • Identify as a TW or as a female or transfeminine person with male sex assigned at birth • Desire to initiate or restart FHT
Principal Investigator